ReviewThe New England journal of medicine2021
Diffuse Large B-Cell Lymphoma.
Review in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 736 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
736 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Pooled it
- Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.Journal of comparative effectiveness research · 2026Pooled it
- Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.Blood cancer journal · 2026Pooled it
- Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.Blood advances · 2026Pooled it
- Trial
- Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.International journal of clinical oncology · 2026Trial
- R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.BMC medicine · 2026Trial
- Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.Blood cancer journal · 2026Trial
- Trial
- ZR2-miniCHOP for elderly patients with newly diagnosed diffuse large B-cell lymphoma.BMC cancer · 2026Trial
- Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.Blood advances · 2026Trial
- Neoplastic CD3⁺ B cells remodel the DLBCL tumor microenvironment via single-cell and spatial transcriptomics.Cancer biology & therapy · 2026Article
- NADPharmaceutical science advances · 2026Article
- The burdens, coping strategies, and unmet needs of family caregivers of Chinese patients with lymphoma receiving commercial CAR-T-cell therapy: A qualitative study.Asia-Pacific journal of oncology nursing · 2026Article
- Role of Surgical Therapy in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Development of a Survival Nomogram.Annals of surgical oncology · 2026Article
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.Blood advances · 2026Article
- From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma.Diagnostics (Basel, Switzerland) · 2026Review
- Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma.Leukemia · 2026Article
676 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.